Despite improvements in both disease-free survival and overall survival (OS) in early-stage HER2-positive breast cancer, long-term follow-up results indicate that approximately 15–24% of patients still develop recurrent disease14,15. This evidence concerns the gene ERBB2 and breast carcinoma.